Angiotensin converting enzyme (ACE) inhibitors improve symptoms, reduce hospitalization, and prolong survival in patients with symptomatic heart failure associated with moderate to severe LVSD both early following myocardial infarction and in the setting of chronic heart failure regardless of the underlying etiology [52, 53, 55, 58, 65]. The gene discussed is ACE; the disease is congestive heart failure.